Recommendations for Broader Coverage Antifungal Prophylaxis in Childhood Acute Myeloid Leukemia: ASH Evidence-Based Review 2011
Author(s) -
M. Monica Gramatges,
Stuart S. Winter
Publication year - 2011
Publication title -
hematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.532
H-Index - 43
eISSN - 1520-4391
pISSN - 1520-4383
DOI - 10.1182/asheducation-2011.1.374
Subject(s) - medicine , fungemia , neutropenia , fluconazole , aspergillosis , empiric therapy , myeloid leukemia , amphotericin b , febrile neutropenia , intensive care medicine , chemotherapy , surgery , mycosis , dermatology , pathology , immunology , antifungal , alternative medicine
A 16-year-old female diagnosed with acute myeloid leukemia (AML) with inversion 16, a favorable prognostic indicator, has persistent neutropenia after her fourth cycle of dose-intensified chemotherapy. She was recently admitted for treatment with empiric antibiotics for febrile neutropenia, and an astute intern noticed a new lesion on her right foot with a dark necrotic center. A biopsy of the lesion showed spreading hyphae, consistent with Aspergillus. Despite her compliance with fluconazole fungal prophylaxis, computed tomography imaging revealed disseminated aspergillosis involving her lungs, liver, and kidneys. Amphotericin was started, but systemic fungemia and the development of multiorgan failure resulted in her death. You are in the difficult position of having to explain to her parents that she died in remission from chemotherapy-related complications. All of those involved in this unfortunate scenario wonder if something could have been done to prevent her death.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom